BioSpace News Archive

Business

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

Intellia Therapeutics today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.

February 27, 2020

·

13 min read

Biotech Beach

aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

Paper highlights the essential role thathistidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states

February 27, 2020

·

5 min read

Genetown

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020

Chiesi Global Rare Diseases announced its support for Rare Disease Day 2020 and highlighted the company’s continued commitment to understanding and addressing the needs of patients living with rare diseases around the world.

February 27, 2020

·

3 min read

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced its support for Rare Disease Day 2020.

February 27, 2020

·

3 min read

Biotech Beach

Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020, at 8:40 a.m. Eastern Time.

February 27, 2020

·

2 min read

Policy

Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet SyndromePDUFA target action date extended by three months to June 25, 2020

Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that the U.S. Food and Drug Administration has extended the review period for the New Drug Application for FINTEPLA® for the treatment of seizures associated with Dravet syndrome.

February 27, 2020

·

3 min read

Deals

NuVasive, Inc. Announces Pricing Of Offering Of $450 Million Of 0.375% Convertible Senior Notes Due 2025

NuVasive, Inc. announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

February 27, 2020

·

9 min read

Business

Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma On-Track for Q2 2020 and Q4 2020, Respectively

February 27, 2020

·

8 min read

Biotech Beach

Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK Partners Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thursday Feb 27 at 11:00-11:25 AM (Presentation Room Adams).

February 27, 2020

·

6 min read

FDA

Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%, 50mEq/50mL (1mEq/mL) Single-Dose Prefilled Syringe.

February 27, 2020

·

3 min read